4 hours VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline AdvancementsZacks
Viking Therapeutics’ third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.
XViking Therapeutics’ third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.
X